Events

 

Upcoming Events

 

June 6 - 9, 2017, San Francisco, CA

Genomics & Big Data Summit

Link: https://www.gtcbio.com/conferences/genomics-big-data-summit-overview?alias=genomics-big-data-summit

 

June 12 - 16, 2017, Boston, MA

Thomas Kleen, PhD, Exec. VP Immune Monitoring, Epiontis, will speak at the WBC Inaugural "Phenotypic and Genotypic Cell Analysis in Immuno-Oncology".

Link: http://www.worldpreclinicalcongress.com/Cell-Analysis-Immunotherapy/

 

August 15 - 18, 2017, Washington, D.C.

Thomas Kleen, PhD, Exec. VP Immune Monitoring, Epiontis, will speak at the Next Generation Diagnostics Summit 2017.

Link: http://www.nextgenerationdx.com/

 

October 19 - 20, 2017, Boston, MA

Novel Cancer Therapeutics Summit

Link: https://www.gtcbio.com/conferences/cancer-therapeutics-summit-overview?alias=cancer-therapeutics-summit

 

Previous Events

 

April 12 - 13, 2017, Lisbon, Portugal

Thomas Kleen, PhD, Exec. VP Immune Monitoring, Epiontis, spoke at the Biomarkers for Immunotherapy Conference as part of the Molecular Diagnostics Europe.

Link: http://www.moleculardxeurope.com/Immunotherapy-Biomarkers/

 

March 20 - 22, 2017, San Diego, CA

Thomas Kleen, PhD, Exec. VP Immune Monitoring at Epiontis, spoke at the Biomarker Summit 2017
by GTCbio.

Link: https://www.gtcbio.com/conferences/biomarkers-summit-agenda

 

February 6 - 7, 2017, San Diego, CA

Ulrich Hoffmüller, PhD, MBA, CBO and Founder of Epiontis, spoke at the ImmunoTX Summit
by GTCbio.

Link: https://www.gtcbio.com/conferences/immunotx-summit-agenda

 

November 8 - 9, 2016, San Fransisco, CA

Thomas Kleen, PhD, Exec. VP Immune Monitoring, Epiontis, spoke at the 5th Cancer Epigenetics Conference by GTCbio.

Link: https://www.gtcbio.com/conferences/cancer-epigenetics-agenda

 

November 1 - 2, 2016, Boston, MA

Thomas Kleen, PhD, Exec. VP Immune Monitoring, Epiontis, spoke at the Cancer Immunotherapy Conference 2016 by GTCbio.

Link: http://selectbiosciences.com/conferences/index.aspx?conf=CIBB2016

 

October 5 - 7, 2016, Berlin, Germany

Ulrich Hoffmüller, PhD, MBA, CBO and Founder of Epiontis, spoke at the Biomarker Summit Europe 2016 by GTCbio.

Link: https://www.gtcbio.com/conferences/biomarker-summit-europe-overview

 

June 3 - 7, 2016, Chicago, Il

Thomas Kleen, PhD, Exec. VP Immune Monitoring, Epiontis, attended the 2016 ASCO Annual Meeting.

Link: http://www.am.asco.org

 

April 5 - 6, 2016, Boston, MA

Thomas Kleen, PhD, Exec. VP Immune Monitoring, Epiontis, spoke at the Phacilitates Oncology Leaders Forum 2016

Link: http://www.bostonleaders.com

 

March 21 - 23, 2016, San Diego, CA

Ulrich Hoffmüller, PhD, MBA, CBO and Founder of Epiontis, spoke at the Biomarker Summit 2016 by GTCbio.

Link: https://www.gtcbio.com/conferences/biomarkers-summit-overview

 

January 25 - 26, 2016, San Diego, CA

Ulrich Hoffmüller, PhD, MBA, CBO and Founder of Epiontis, spoke at the 8th Immunotherapeutics and Immunomonitoring Conference by GTCbio.

Link: https://www.gtcbio.com/conferences/immunotherapeutics-immunomonitoring-overview

 

October 5 - 8, 2015, Berlin, Germany

Ulrich Hoffmüller, PhD, MBA, CBO and Founder of Epiontis, spoke at the Biomarker Summit Europe 2015 by GTCbio.

Link: https://www.gtcbio.com/conferences/biomarker-summit-europe-overview

 

September 9 - 11, 2015, Philadelphia, PA

Thomas Kleen, PhD, Exec. VP Immune Monitoring, Epiontis spoke at the Anti-Inflammatory Research & Therapeutics Conference 2015 by GTCbio.

Link: https://www.gtcbio.com/conferences/anti-inflammatory-research-therapeutics-overview

 

May 29 - June 2, 2015, Chicago, Il

Thomas Kleen, PhD, Exec. VP Immune Monitoring, Epiontis, attended 2015 ASCO Annual Meeting.

Link: http://am.asco.org

 

May 20 - 22, 2015, Halle, Germany

Thomas Kleen, PhD, Exec. VP Immune Monitoring, Epiontis, attended Tumor Immunology Meets Oncology Meeting.


Link: http://www.medizin.uni-halle.de/index.php?id=5214

 May 8 - 12, 2015, New Orleans, LA

Thomas Kleen, PhD, Exec. VP Immune Monitoring, Epiontis, attended Immunology 2015 AAI Annual Meeting.


Link: http://immunology2015.org/

  1. Privacy Statement: Your phone number or email address will be exclusively used to contact you and will not be given to any third party.